The study investigates the combined therapeutic efficacy of hormone replacement therapy (HRT), repetitive transcranial magnetic stimulation (rTMS), and ibogaine therapy in veterans with PTSD and TBI related cognitive impairment. It’s the first study of its kind to evaluate all three therapeutic modalities in concert, with the aim of identifying the optimal order of treatments. Veterans suffering from PTSD and TBI often experience endocrine dysfunction, diminished neural activity, and reductions in neuroplasticity. When taken together, HRT, rTMS, and ibogaine therapy address the core maladies of PTSD and TBI by restoring healthy endocrine functioning, promoting neural activity through non-invasive magnetic stimulation, and activating neuroplastic changes through the production of brain-derived neurotrophic factor, respectively. Most importantly, these treatments have been endorsed by veterans and represent the cutting edge of veterans’ health.